Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

NGEN

NervGen Pharma Corp

Apr 28 • 04:00PM ET

3.88

+0.03 0.78 %

Healthcare • Biotechnology • Canada • Small • NASD

Apr 27, 7:35 AMNervGen Pharma appoints Keith Vendola, MD, MBA, as Chief Financial Officer, effective immediately.

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.42	Insider Own	21.45%	Shs Outstand	79.65M	Perf Week	0.00%
Market Cap	314.01M	Forward P/E	-	EPS next Y	-0.36	Insider Trans	0.00%	Shs Float	63.57M	Perf Month	6.01%
Enterprise Value	297.91M	PEG	-	EPS next Q	-0.07	Inst Own	0.48%	Short Float	2.01%	Perf Quarter	-16.20%
Income	-31.64M	P/S	-	EPS this Y	27.02%	Inst Trans	0.32%	Short Ratio	7.85	Perf Half Y	41.09%
Sales	0.00M	P/B	121.82	EPS next Y	-13.37%	ROA	-207.62%	Short Interest	1.27M	Perf YTD	-30.71%
Book/sh	0.03	P/C	19.49	EPS next 5Y	24.06%	ROE	-1462.20%	52W High	6.30 -38.41%	Perf Year	80.47%
Cash/sh	0.20	P/FCF	-	EPS past 3/5Y	-13.03% -10.94%	ROIC	-1247.48%	52W Low	1.50 158.67%	Perf 3Y	234.48%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.17% 6.52%	Perf 5Y	169.44%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-67.10%	Oper. Margin	-	ATR (14)	0.25	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.16	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	44.98	Recom	1.14
Dividend Gr. 3/5Y	- -	Current Ratio	1.16	EPS Q/Q	-186.86%	SMA20	-4.70%	Beta	0.95	Target Price	10.67
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-3.82%	Rel Volume	0.72	Prev Close	3.85
Employees	8	LT Debt/Eq	0.00	Earnings	Mar 31 BMO	SMA200	9.53%	Avg Volume	162.30K	Price	3.88
IPO	Apr 03, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	-125.72% -	Trades		Volume	118,580	Change	0.78%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-27-26	Initiated	H.C. Wainwright	Buy	$18

Apr-27-26 07:30AM	NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer (GlobeNewswire)
Apr-13-26 07:45AM	NervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference (GlobeNewswire)
Apr-07-26 07:30AM	NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia (GlobeNewswire) -9.57%
Mar-31-26 07:45AM	NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-12-26 04:15PM	NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange (GlobeNewswire) -6.98%
07:30AM	Loading…
Mar-04-26 07:30AM	NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs (GlobeNewswire) +8.10%
Feb-18-26 07:30AM	NervGen Pharma to Participate at Upcoming Investor Conferences (GlobeNewswire)
Feb-12-26 04:15PM	NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams (GlobeNewswire)
Feb-11-26 07:00AM	NervGen Pharma to Present at Unite2Fight Paralysis' 20th Annual Science and Advocacy Symposium (GlobeNewswire)
Feb-09-26 07:00AM	NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company's Growth and Execution of Its Mission in Spinal Cord Injury (GlobeNewswire)
Jan-20-26 07:00AM	NervGen Pharma to Ring the Nasdaq Closing Bell on January 22, 2026, Celebrating Its Recent Nasdaq Listing (GlobeNewswire) -6.93%
Jan-08-26 06:30AM	NervGen Pharma Begins Trading on Nasdaq Today (GlobeNewswire)

NervGen Pharma Corp. operates as a clinical stage biotech company. It provides development of treatment that enables the nervous system to repair itself following damage, whether due to injury or disease. The company was founded by Harold Punnett and William Joseph Radvak on January 19, 2017 and is headquartered in Vancouver, Canada.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NGEN

NervGen Pharma Corp

Upgrade your Finviz experience